AAREY DRUGS & PHARM Latest Share Price (AAREYDRUGS)
TODAY IN ONE LINE
AAREYDRUGS fell 1.4% on above-average volume (707697.8x avg), in line with Nifty's -0.5% move.
With a market cap of ₹345.36 Cr., it trades at a P/E of 72.86. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
AAREY DRUGS & PHARM flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Promoter BuyingPromoters increased holdings by 5.08% QoQ
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 41.0% YoY
- ●Poor Capital ReturnsLow ROE of 2.6%
Latest AAREY DRUGS & PHARM News
What changed recently?
Recent events, corporate actions, and announcements.
AAREY DRUGS & PHARM valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for AAREY DRUGS & PHARM, framed against the sector median so the premium or discount is obvious at a glance.
AAREY DRUGS & PHARM trades at a P/E of 72.86× and P/B of 2.02×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
AAREY DRUGS & PHARM technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for AAREY DRUGS & PHARM — derived from the latest tape, not yesterday's close.
AAREY DRUGS & PHARM last traded at ₹110.41 with an intraday range of ₹108.01–₹114 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹110.41| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 125.58 | +15.17 | +13.74% |
| R3 | 119.59 | +9.18 | +8.32% |
| R2 | 116.80 | +6.39 | +5.78% |
| R1 | 113.60 | +3.19 | +2.89% |
| PIVOT | 110.81 | 0.40 | 0.36% |
| CURRENT | 110.41 | — | — |
| S1 | 107.61 | -2.80 | -2.53% |
| S2 | 104.82 | -5.59 | -5.07% |
| S3 | 101.62 | -8.79 | -7.96% |
| S4 | 95.63 | -14.78 | -13.38% |
AAREYDRUGS is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹110.5–₹111.93
Trading Inside opening range
AAREY DRUGS & PHARM financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for AAREY DRUGS & PHARM — consolidated or standalone — with margins, YoY growth and key ratios inline.
AAREY DRUGS & PHARM reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹345.36 Cr. and reported EPS of ₹1.47.
AAREY DRUGS & PHARM segment analysis : revenue and profit mix.
Disclosed business segments at AAREY DRUGS & PHARM with their share of revenue and profit, switchable between consolidated and standalone reporting.
AAREY DRUGS & PHARM discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for AAREY DRUGS & PHARM.
Our AI distills the core fundamental drivers supporting AAREY DRUGS & PHARM, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
AAREY DRUGS & PHARM's investment case rests on 5 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Niche focus on Active Pharmaceutical Ingredients and specialty chemicals manufacturing.
Adequate short-term liquidity with a current ratio of 1.81x in FY2026.
Low leverage profile, total borrowings of ₹49.96 Cr and D/E ratio 0.33x.
Operating cash flow of ₹10.14 Cr in FY2026 exceeded net profit.
Latest quarterly EPS showed an 11.99% YoY increase.
Key Risks.
Critically low ROE of 2.64% and ROCE of 3.84% below peer median.
5-year EPS CAGR of -10.51% and 3-year EPS CAGR of -19.42%.
Negative free cash flow of ₹-2.27 Cr in FY2026 signals cash burn.
Latest quarterly revenue declined 76.45% YoY, indicating sharp deceleration.
TTM EPS growth declined by 41.05% YoY, highlighting underlying earnings weakness.
Flip Conditions.
Valuation risk. a P/E above 95 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
AAREY DRUGS & PHARM peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — AAREY DRUGS & PHARM is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
AAREY DRUGS & PHARM chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for AAREY DRUGS & PHARM — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
AAREY DRUGS & PHARM delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for AAREY DRUGS & PHARM over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in AAREY DRUGS & PHARM stood at 74.7% of traded volume, against a 20-day average of 65.9%.
AAREY DRUGS & PHARM announcements: results, concalls, ratings, M&A.
Filings AAREY DRUGS & PHARM sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
AAREY DRUGS & PHARM files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 51 documents below.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
General Updates
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about General Updates
Shareholders meeting
Aarey Drugs & Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report and voting results of Annual General Meeting held on…
Disclosure of material issue
Aarey Drugs & Pharmaceuticals Limited has informed regarding Disclosure of material issue
Disclosure of material issue
Aarey Drugs & Pharmaceuticals Limited has informed regarding Disclosure of material issue
AAREY DRUGS & PHARM dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue AAREY DRUGS & PHARM has declared, sequenced by announce and record date.
AAREY DRUGS & PHARM corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About AAREY DRUGS & PHARM: business, sector, key facts.
What AAREY DRUGS & PHARM does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
AAREY DRUGS & PHARM operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: AAREYDRUGS, BSE: 524412.
Aarey Drugs & Pharmaceuticals Limited is an Indian company established in 1990 and headquartered in Mumbai. Its core business revolves around the manufacturing and sale of a diverse range of chemical products, primarily targeting the pharmaceutical and industrial sectors.
A significant portion of Aarey's business focuses on the production and supply of Active Pharmaceutical Ingredients (APIs). These APIs, which are crucial components in the manufacturing of various pharmaceuticals, include key substances such as metformin HCL, mefenamic acid, and doxophylline. These products are directly sold to pharmaceutical formulation manufacturers and exporters, playing a vital role in the broader pharmaceutical supply chain.
Beyond APIs, Aarey also produces and sells a wide array of intermediates and specialty chemicals utilized in various industrial applications. This extensive catalog encompasses a diverse range of chemical compounds, including mono methyl and die methyl urea, ortho para nitro anisole, 2 bromomethyl 1,3 dioxalane, and uracile. The company’s industrial chemical offerings extend to solvents, aromatic chemicals, acids, chlor alkalies, glycols and glycol ethers, fiber intermediates, acetates and esters, chlorinated solvents, alcohols, ketones, amines, oleochemicals, olefines, phosphates, fertilizers, and monomers.
In addition to its manufacturing operations, Aarey Drugs engages in the trading of industrial solvents and chemicals, further expanding its reach and product portfolio within the chemical industry. This trading activity complements its manufacturing business, providing a broader service offering to its customers and contributing to the overall revenue streams of the company.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- ALBERT DAVID (ALBERTDAVD) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Other overvalued NSE stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about AAREY DRUGS & PHARM (AAREYDRUGS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of AAREY DRUGS & PHARM (AAREYDRUGS)?
The current share price of AAREY DRUGS & PHARM (AAREYDRUGS) is ₹110.41. Today, the stock has declined by ₹1.52 (1.36%), trading in a range of ₹108.01 to ₹114.00. The stock opened at ₹111.93 with a trading volume of 2,08,417 shares.
02Is AAREY DRUGS & PHARM stock a good investment for long-term?
AAREY DRUGS & PHARM can be considered for long-term investment based on several factors. The company has a market capitalization of ₹345.36 Cr., P/E ratio of 72.86, ROE of 2.64%, and ROCE of 3.84%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of AAREY DRUGS & PHARM stock?
The 52-week high price of AAREY DRUGS & PHARM (AAREYDRUGS) is ₹114.80, while the 52-week low is ₹50.31. Currently trading at ₹110.41, the stock is 119.46% above its 52-week low and 3.82% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy AAREY DRUGS & PHARM stock at the current price?
Whether to buy AAREY DRUGS & PHARM stock at ₹110.41 depends on multiple factors. The stock is currently trading with a P/E ratio of 72.86 and P/B ratio of 2.02. Today's performance shows a loss of 1.36%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of AAREY DRUGS & PHARM and when is the next dividend?
AAREY DRUGS & PHARM offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹110.41, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of AAREY DRUGS & PHARM?
AAREY DRUGS & PHARM's key financial metrics include: P/E Ratio: 72.86, P/B Ratio: 2.02, ROE: 2.64%, ROCE: 3.84%, Dividend Yield: 0%, EPS: ₹1.47, Book Value: ₹52.87, and Debt-to-Equity: 0.33. The company's market cap stands at ₹345.36 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is AAREY DRUGS & PHARM stock performing today in the market?
AAREY DRUGS & PHARM stock opened at ₹111.93 and is currently trading at ₹110.41, showing a decline of ₹1.52 (1.36%). The intraday high is ₹114.00 and low is ₹108.01. The trading volume stands at 2,08,417 shares, indicating moderate market participation today.
08What is the P/E ratio of AAREY DRUGS & PHARM and what does it indicate?
AAREY DRUGS & PHARM has a Price-to-Earnings (P/E) ratio of 72.86, which means investors are willing to pay 72.86 for every ₹1 of earnings. With an EPS of ₹1.47, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about AAREY DRUGS & PHARM (AAREYDRUGS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.